Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00584935 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
A Phase 1 study of Ocular Cicatricial Pemphigoid, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT00584935 is a Phase 1 study of Ocular Cicatricial Pemphigoid that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 3 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00584935, a Phase 1 study of Ocular Cicatricial Pemphigoid, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead to irreversible damage and blindness. Conventional treatments include systemic steroids, dapsone, and immunosuppressive agents. These treatments, however, are not successful with all patients. Rituximab has been very effective in the treatment of other autoimmune disorders, and has recently been shown to be effective for autoimmune blistering pemphigus. We propose that it will also be effective in the treatment of cicatricial pemphigoid.
Conditions Studied
Interventions
- DRUG Rituximab
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2006-01 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00584935
The ClinicalTrials.gov registry entry for NCT00584935 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ocular Cicatricial Pemphigoid appearing as the primary indexed condition, and to 1 intervention - of which Rituximab is the first listed.
NCT00584935 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT00584935 about?
NCT00584935 is a clinical study titled "Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid". Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead to irreversible damage and blindness. Conventional treatments include systemic steroids, dapsone, and immunosuppressiv...
What is the current status of trial NCT00584935?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2006-01. Estimated completion is 2010-05.
What conditions does trial NCT00584935 study?
This clinical trial studies the following conditions: Ocular Cicatricial Pemphigoid.
What interventions are being tested in trial NCT00584935?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT00584935?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00584935 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Cicatricial Pemphigoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.